Convenience matters, but so does choosing the right wellness service for the right person
While federal law has long carved out exceptions for pharmacists to mix custom medications for individual patients, the sheer scale of current operations has blurred the line between traditional pharmacy practice and unapproved manufacturing. For intellectual property (IP) attorneys, regulatory affairs directors, and biopharma executives, the urgent question is no longer theoretical: At what point does the volume, scale, and marketing of a compounded drug cease to be a regulatory exemption and become actionable patent infringement
Is the patient ready for progressive resistance training
Transfection and transgene expression in a human kidney during ex vivo warm perfusion
Compared with control group, serum levels of malondialdehyde and neutrophil to lymphocyte ration (NLR) significantly decreased in the intervention group
Commercial non-food products derived from M